Novel Pathways Regulating Function and Metabolism of ß-Amyloid Precursor Protein in Alzheimer's Disease by Yun-Wu Zhang et al.
16
Produced by the Science/AAAS Custom Publishing Office
17
NEURODEGENERATION RESEARCH
Alzheimer’s disease (AD) is the most common neurodegenera-
tive disorder worldwide, defined by two classical hallmark pa-
thologies: extracellular senile plaques and intraneuronal neu-
rofibrillary tangles (NFTs) (1,	 2). NFTs are composed of the 
hyperphosphorylated microtubule-associated protein tau that is 
abnormally phosphorylated primarily by glycogen synthase ki-
nase-3 (GSK-3) and cyclin D kinase 5 (Cdk5) (2). Senile plaques 
are composed of heterogeneous small peptides collectively 
called β-amyloid (Aβ), derived from the β-amyloid precursor pro-
tein (APP) through sequential cleavage by β- and γ-secretases. 
APP is synthesized in the endoplasmic reticulum (ER) and trans-
ported through the Golgi/trans-Golgi network (TGN) to the plasma 
membrane, where it can be cleaved by α-secretase to produce 
sAPPα. Non-cleaved APP is re-internalized and is subjected to 
amyloidogenic processing for Aβ generation (1). Multiple lines of 
evidence suggest that overproduction/aggregation of Aβ in the 
brain is the primary cause of AD: Aβ is highly toxic to neurons 
and can trigger a cascade of pathogenic events leading to cell 
death. Therefore, detailed delineation of the function, process-
ing, and regulated trafficking of APP is crucial for understanding 
the mechanism underlying AD pathogenesis and for developing 
AD therapeutic strategies. 
App proCessing TowArDs Aß generATion
Full-length APP is a type I transmembrane protein transported 
through the constitutive secretory pathway. During its endocytic 
trafficking, APP can first be cleaved by β-secretase to release 
a soluble APP extracellular domain called sAPPβ. The remain-
ing membrane-associated APP carboxyl-terminal fragment-β (β 
CTF) can then be cleaved by γ-secretase to generate Aβ and an 
APP intracellular domain (AICD).  
The type I transmembrane aspartyl protease beta-site APP-
cleaving enzyme (BACE1) is the primary β-secretase species. 
Optimal enzymatic BACE1 activity requires acidic environments 
such as those found in the TGN and endosomes where BACE1 
is present in abundance (3). Mechanisms regulating BACE1 traf-
ficking and activity have not been fully elucidated. Sorting nexin 
(SNX) family members contain a conserved lipid-binding PX do-
main and play important roles in membrane trafficking and pro-
tein sorting (4). We recently found that a member of the SNX 
family, SNX12, interacts with BACE1. Downregulation of SNX12 
accelerates BACE1 endocytosis, thus increasing Aβ production, 
whereas overexpression of SNX12 has the opposite effect. In ad-
dition, SNX12 levels are decreased in AD brains, suggesting that 
changes in SNX12 levels may contribute to AD pathology (5). We 
also found that the human CUTA protein, another novel protein 
that interacts with BACE1, regulates its intracellular trafficking. 
Downregulation of CUTA can decelerate intracellular trafficking 
of BACE1 from the Golgi/TGN to the cell surface and increase 
BACE1-mediated APP processing/Aβ generation (6). 
In addition to its function as a β-secretase for APP, we recently 
found that BACE1 may also contribute to memory and cogni-
tive deficits associated with AD through an Aβ-independent 
mechanism: BACE1 interacts with adenylate cyclases via its 
transmembrane domain, resulting in a reduction in cellular cAMP 
levels and thus decreased protein kinase A (PKA) activity and 
CREB phosphorylation (7). Interestingly, during our search for 
new genes that regulate Aβ generation, we identified a new gene 
family, designated Rps23rg, whose encoded proteins also inter-
act with adenylate cyclases via their transmembrane domains. 
However, RPS23RG proteins increase cellular cAMP levels to 
activate PKA, causing increased CREB phosphorylation and 
GSK-3 phosphorylation. Phosphorylation of GSK-3 inhibits its 
activity, resulting in reduced Aβ generation and tau phosphoryla-
tion (8,	9).
γ-cleavage is the last step in APP processing to generate Aβ 
peptides. In addition to cleaving APP, the high molecular mass, 
membrane-bound γ-secretase complex cleaves many other sub-
strates such as Notch, Cadherin, and ErbB4. γ-secretase con-
sists of four essential components: presenilin (PS, PS1, or PS2), 
nicastrin, anterior pharynx-defective-1 (APH-1), and presenilin 
enhancer-2 (PEN-2). We and others have shown that deficiency 
in any one of these may dramatically affect the stability and in-
tracellular trafficking of other components and impair γ-secretase 
activity (1). 
PS1 is the catalytic component of the γ-secretase complex. 
In addition to cleaving γ-secretase substrates, PS1 has been 
shown to have other functions, some of which are independent of 
γ-enzymatic activity. For example, we and others show that PS1 
can reciprocally regulate the intracellular trafficking of APP (see 
next page) as well as several other membrane proteins (1,	10). 
funCTionAl roles for App AnD iTs meTAboliTes
Since its identification as the precursor of Aβ, APP has been 
studied extensively. However, the physiological function of APP 
remains largely undetermined. APP is proteolyzed into various 
fragments during intracellular trafficking and these APP metabo-
lites mediate various and sometimes opposing functions. The net 
effect of APP on cellular activity may be determined by the rela-
tive amounts of APP itself and its various metabolites.
In cells and brains deficient in APP, we observed an elevation 
of Cdk5 activity where tau phosphorylation can be inhibited by 
re-expressing APP or sAPPα. In addition, APP-deficient neurons 
exhibit reduced metabolism and survival rates and are more sus-
ceptible to excitotoxic glutamate-induced apoptosis through a 
mechanism involving Cdk5 activation. Our results define a novel 
neuroprotective function for APP, specifically the extracellular 
APPα domain, in preventing tau hyperphosphorylation through 
the suppression of Cdk5 overactivation (11). 
APP undergoes rapid anterograde transport in neurons. Dur-
ing its transport, APP interacts with kinesin-I and functions as 
a membrane-associated kinesin-I receptor to mediate axonal 
transport of β-secretase and PS1 (12,	13). We find that APP can 
regulate cell surface delivery of the PS1/γ-secretase; APP de-
ficiency accelerates transport of PS1 from the TGN to the cell 
surface and increases cell surface levels of PS1, which can be 
reversed by restoring APP levels (14). APP dosage also mark-
edly decreases retrograde transport of nerve growth factor (15). 
Moreover, APP interacts with the choline transporter and affects 
its endocytosis (16). Together, these findings suggest that APP 
plays a critical role in regulating protein trafficking.
Using AICD as bait, we identified a mitochondrial carrier protein 
as an APP-interacting protein and designated it as appoptosin. 
We found that elevated appoptosin-mediated heme biosynthesis 
induced the release of reactive oxygen species and activated 
intrinsic caspase-dependent apoptosis. Importantly, appopotosin 
levels were upregulated in neurons treated with Aβ and in AD 
brains, whereas downregulation of appoptosin prevents cell 
death and caspase activation caused by Aβ insult, thereby 
implicating a novel appoptosin-dependent mechanism underlying 
Aβ neurotoxicity. Moreover, we found that although APP interacts 
with appoptosin through the AICD domain, AICD was unable to 
rescue appoptosin-induced cell death. These results suggest 
that membrane-associated domains in the full-length APP and 
APP CTFs are required to inhibit appoptosin-induced apoptosis. 
Hence, membrane-anchored APP may interact with and retain 
a certain amount of appoptosin in the cytosol, thus keeping the 
level of appoptosin in mitochondria from being elevated for more 
heme production in the presence of cellular insults or under 
pathological conditions. Since membrane-dissociated AICD has 
little effect on appoptosin-induced caspase activation, this could 
imply that membrane-associated APP/appoptosin complexes 
can be released and transported to mitochondria upon 
γ-cleavage to increase heme synthesis and apoptosis. These 
results demonstrate a function of APP in mediating trafficking of 
nascent appoptosin from the cytosol to mitochondria (17). 
Cytosolic AICD within the cell may translocate into the nucle-
us to regulate the transcription of several genes such as APP, 
GSK-3β, BACE1, and low density lipoprotein receptor-related 
protein 1 (LRP1) (18). We also find that AICD can bind to the 
promoter region of the epidermal growth factor receptor (EGFR) 
gene and regulate its expression. Consistent with the notion that 
dysregulation of EGFR expression and activation is involved in 
cancers, we found that PS1/γ-secretase deficient mice have in-
creased EGFR levels and increased tumorigenesis, in particular 
skin cancer. As AICD is generated concurrently with Aβ, which 
is elevated in AD, our results imply that there is a negative cor-
relation between AD and cancer incidence and that the strategy 
for inhibiting PS1/γ-secretase activity to treat AD may increase 
the risk of tumorigenesis. Both implications are supported by 
recent findings that epidemiological studies have identified an 
inverse association between cancer and AD (19), while AD clini-
cal trials of the γ-secretase inhibitor semagacestat from Eli Lilly 
have demonstrated that patients receiving the drug have an in-
creased risk of skin cancer compared with those who received 
a placebo. 
regulATion of App inTrACellulAr TrAffiCking
Subcellular APP trafficking to divergent sAPPα or Aβ cleavage 
pathways is critical to neurodegenerative onset, and mecha-
nisms underlying APP trafficking are therefore integral to deter-
mining neuropathological AD outcome. We found that SNX17 
can interact with APP in the early endosome and that downregu-
lation of SNX17 leads to reduced APP levels with a concomitant 
increase in Aβ (20). In addition, we and others have demonstrat-
ed that members of the low-density lipoprotein (LDL) receptor 
family, including LRP1, LRP1B, SorLA/LR11, and apolipoprotein 
E receptor 2, interact with APP and regulate its endocytic traf-
ficking and Ab generation. Moreover, we have shown that one of 
the γ-secretase components, PS1, also regulates APP traffick-
ing where loss of PS1 results in increased budding/generation of 
APP-containing vesicles from both the ER and TGN, along with 
a concomitant increase in cell surface localization of APP. More-
over, familial AD-linked PS1 variants are significantly impaired in 
vesicle budding, thereby attenuating cell surface delivery of APP 
(10). We also found that PS1 interacts with phospholipase D1 
(PLD1), a phospholipid-modifying enzyme regulating membrane 
trafficking events, and recruits PLD1 to the Golgi/TGN, thus po-
tentially altering APP trafficking. Indeed, PLD1 overexpression 
promotes budding of APP vesicles from the TGN, concomitant-
ly increasing cell surface levels of APP (21,	22).
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causes tau hyperphosphorylation at 
several sites related to impairment 
of spatial memory in AD (8). Mul-
tiple factors can cause tau hyper-
phosphorylation through GSK-3β 
activation, including peroxide nitrite 
(9), advanced glycation end prod-
ucts (10,	11), persistent light illumi-
nation (12), endoplasmic reticulum 
stress (13,	14), Aβ (8,	15), and pro-
teasome dysfunction (16,	17). While 
activating GSK-3β inhibits long-term 
potentiation (LTP), inhibiting it pro-
motes LTP through mechanisms 
involving the presynaptic release of 
neurotransmitter (18,	 19). Inhibiting 
GSK-3β significantly attenuates tau 
hyperphosphorylation and improves 
memory (20,	21), while overexpres-
sion of neuroprotective neuroglobin 
decreases tau hyperphosphorylation 
by inhibiting GSK-3β (22,	23).
In the brains of rats, inhibition of 
phosphatidylinositol 3-kinase (PI3K) 
alone induces a transient activation 
of GSK-3β, while simultaneous inhibition of PI3K and protein ki-
nase C (PKC) results in a sustained activation of GSK-3β, lead-
ing to prolonged tau hyperphosphorylation and spatial memory 
deficits with reduction of acetylcholine (8,	24,	25). Phosphoryla-
tion of GSK-3β at serine-9 is recognized to be negatively corre-
lated with GSK-3β activation, while cleavage of GSK-3β by cal-
pain counteracts the inhibitory effect of serine-9 phosphorylation 
on GSK-3β activity induced by hydrogen peroxide (26).
Phosphorylation of tau by protein kinase A (PKA) primes tau, 
making it a better substrate for GSK-3β, and at least partially 
explaining why the GSK-3β-preferred sites on tau can be hyper-
phosphorylated even after transient activation by PKA (27,	28). 
Interestingly, we demonstrated that tau hyperphosphorylation by 
GSK-3β seemed to be required for hippocampal neurogenesis 
in the dentate gyrus. Further, tau phosphorylation and GSK-3β 
activation are essential for the adult neurogenesis in the subven-
tricular zone (SVZ), another niche of neurogenesis in the adult 
brains (29,	 30), suggesting that the neurogenesis in the brain 
may be tightly regulated by local microenvironments. 
Due to its role in tau phosphorylation, GSK-3β has been con-
sidered as a drug target for inhibiting neurodegeneration. How-
ever, GSK-3β has other functions in the cell, so complete inhibi-
tion would likely be detrimental. Recent studies that attempted 
spatiotemporal targeting of abnormal GSK-3β activation found 
that pathologies and memory deficits in an AD mouse model 
could be effectively attenuated (31). Further studies are needed 
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Tau proteins play an important role in maintaining the stability of 
the neuronal cytoskeleton system. In Alzheimer’s disease (AD), 
tau is abnormally hyperphosphorylated and aggregates into 
paired helical filaments (PHFs) forming neurofibrillary tangles 
(NFTs) in neurons (1). Clinical investigations have shown that the 
intracellular accumulation of NFTs is positively correlated with 
the severity of dementia. The transmission of abnormal tau or 
NFTs from the entorhinal cortex to the hippocampus and cere-
bral cortex matches the clinical manifestation, which is the inter-
national gold standard at present for assessing AD progression 
(Braak grading) (2). Recent studies suggest that the toxicity of 
b-amyloid protein (Ab, another pathogenic factor in AD) needs 
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Figure 1. Schematic summarizing our current understanding of the various signaling pathways through which 
tau acts within the cell. 
to clearly define the conditions, but this work shows promise. 
role of pp2A in TAu hyperphosphorylATion
Tau proteins are dephosphorylated by protein phosphatases 
such as PP2A; therefore, inactivation of phosphatases results 
in tau hyperphosphorylation. PP2A is the most effective at de-
phosphorylating abnormally hyperphosphorylated tau isolated 
from the AD brains (32,	 33). In vitro, PP2A can dephosphory-
late abnormal tau at multiple sites and thus restore its biologi-
cal activity (34). Inhibiting PP2A in vivo by injection of okadaic 
acid or homocystine into the brain, or in vitro by incubating cells 
with PP2A inhibitors, induces AD-like tau hyperphosphoryla-
tion, intracellular accumulation, axoplasmic transport deficits, 
and learning/memory dysfunction (35,	 36). PP2A is activated 
in the astrocytes of tg2567 mice—a widely used amyloido-
genic model of AD—and activation of PP2A stimulates the 
migration of astrocytes to the amyloid plaques through p38 
MAPK inhibition, indicating that PP2A deficits observed in 
AD brains may cause Aβ accumulation by hindering astrocyte 
migration (37). 
Since PP2A activity is significantly inhibited in AD brains, upreg-
ulating PP2A seems a promising therapeutic strategy. However, 
currently no specific activator of PP2A exists, making the search 
for an upstream regulator of PP2A a critical mission. We have 
demonstrated that GSK-3β activation can inhibit PP2A by upreg-
ulating protein tyrosine phosphatase 1Β, which phosphorylates 
genic events in AD. Studies from our group and others have re-
vealed novel pathways by which APP function and processing are 
regulated. Further studies investigating the function and regula-
tion of APP in AD will not only help to elucidate the mechanism 
underlying disease pathogenesis, but also to identify new targets 
for disease treatment.
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the tau protein as a mediator (3). These data together suggest 
that abnormal tau plays an important role in the onset and evolu-
tion of neurodegeneration and the learning/memory deficits in 
AD patients.
To date, no tau gene mutation has been found in the AD pa-
tients. The main focus of tau research therefore has been on 
posttranslational modifications, of which hyperphosphorylation is 
the most extensively studied. The imbalance of protein kinases 
(generally upregulation) and protein phosphatases (generally 
downregulation) is the direct cause for abnormal tau hyperphos-
phorylation. Among various protein kinases and protein phos-
phatases, glycogen synthase kinase-3β (GSK-3β) and protein 
phosphatase-2A (PP2A) are most heavily involved in AD-like tau 
hyperphosphorylation (4–6).
role of gsk-3ß in TAu hyperphosphorylATion
GSK-3β was the first tau kinase to be identified; it can phosphor-
ylate tau at multiple sites	in vitro (7). In vivo activation of GSK-3β 
